Jeff Yass’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-232,100
| Closed | -$4.98M | – | 13577 |
|
|
2026
Q1 | $4.98M | Buy |
232,100
+147,400
| +174% | +$2.08M | ﹤0.01% | 4235 |
|
|
2025
Q4 | $789K | Buy |
84,700
+24,400
| +40% | +$204K | ﹤0.01% | 7716 |
|
|
2025
Q3 | $425K | Buy |
+60,300
| New | +$415K | ﹤0.01% | 9336 |
|
|
2025
Q2 | – | Sell |
-27,800
| Closed | -$220K | – | 12814 |
|
|
2025
Q1 | $220K | Sell |
27,800
-20,500
| -42% | -$221K | ﹤0.01% | 10742 |
|
|
2024
Q4 | $612K | Buy |
48,300
+18,700
| +63% | +$260K | ﹤0.01% | 8183 |
|
|
2024
Q3 | $412K | Sell |
29,600
-12,300
| -29% | -$175K | ﹤0.01% | 8933 |
|
|
2024
Q2 | $577K | Buy |
41,900
+11,000
| +36% | +$161K | ﹤0.01% | 7912 |
|
|
2024
Q1 | $510K | Buy |
30,900
+12,900
| +72% | +$193K | ﹤0.01% | 8468 |
|
|
2023
Q4 | $263K | Sell |
18,000
-2,600
| -13% | -$31.5K | ﹤0.01% | 10107 |
|
|
2023
Q3 | $253K | Sell |
20,600
-16,600
| -45% | -$217K | ﹤0.01% | 9723 |
|
|
2023
Q2 | $444K | Buy |
37,200
+22,500
| +153% | +$294K | ﹤0.01% | 8587 |
|
|
2023
Q1 | $197K | Sell |
14,700
-7,900
| -35% | -$154K | ﹤0.01% | 10616 |
|
|
2022
Q4 | $486K | Buy |
22,600
+12,000
| +113% | +$246K | ﹤0.01% | 7935 |
|
|
2022
Q3 | $212K | Sell |
10,600
-25,200
| -70% | -$536K | ﹤0.01% | 10689 |
|
|
2022
Q2 | $641K | Buy |
+35,800
| New | +$370K | ﹤0.01% | 7656 |
|
Other funds holding DAWN
Jeff Yass's DAWN Position: Q2 2026 in Review
Jeff Yass sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 473,543 shares — an estimated $10.2M sold.
Jeff Yass first reported a position in DAWN in Q1 2022 and held it in 16 quarters. The position peaked at $10.2M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Jeff Yass reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Jeff Yass sold 473,543 Day One Biopharmaceuticals shares in Q2 2026, an estimated $10.2M.
- Jeff Yass first reported a position in Day One Biopharmaceuticals in Q1 2022 and held it in 16 quarters.
- Jeff Yass's Day One Biopharmaceuticals position peaked at $10.2M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.